Ligand Pharmaceuticals (LGND) News Today

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) is trading higher as investors respond to favorable analyst coverage and the company’s new financing agreement with AvenCell Therapeutics. The stock’s recent momentum is also supported by Ligand’s strong earnings growth and pipeline-related opportunities.

• Positive Sentiment: New Barclays coverage: Barclays initiated coverage of Ligand with an “overweight” rating and a $345 price target, implying meaningful upside from the referenced price. The endorsement adds a new positive institutional view of Ligand’s royalty and drug-development platform.
• Positive Sentiment: HC Wainwright remains bullish: The firm reaffirmed its “buy” rating and raised or maintained a $358 price target, indicating confidence in Ligand’s earnings outlook and partnered drug pipeline.
• Positive Sentiment: AvenCell financing expands pipeline exposure: Ligand agreed to provide up to $47 million to AvenCell Therapeutics to advance next-generation, controllable allogeneic CAR-T therapies for cancer. The transaction gives Ligand potential participation in an emerging cell-therapy platform and could create future royalty or milestone opportunities, although returns depend on clinical and commercial success. Ligand and AvenCell Therapeutics financing agreement
• Positive Sentiment: Additional positive analyst sentiment: Citigroup reportedly expects Ligand’s stock to rise, adding to the generally favorable analyst backdrop. Citigroup analyst outlook for Ligand Pharmaceuticals
• Neutral Sentiment: Mixed healthcare-sector views: A broader analyst report describes conflicting sentiment across Amgen, Ligand and Compass Therapeutics; however, the specific recent ratings highlighted for Ligand are favorable. Analyst sentiment on healthcare companies
• Neutral Sentiment: Short-interest data is unclear: A report described a large increase in short interest but listed total short interest at zero shares and a zero-day days-to-cover ratio, suggesting the data may be incomplete or anomalous rather than a meaningful trading signal.